Lyra Therapeutics, Inc..
LYRA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing innovative therapies for ear, nose, and throat (ENT) diseases. The company's primary focus is on developing and commercializing products based on its proprietary XTreo platform, a bioresorbable, polymeric matrix d...Show More
Better Health for All
-20
Lyra Therapeutics' core business was entirely devoted to developing LYR-210, a bioresorbable device for chronic rhinosinusitis (CRS), a condition affecting 14 million people in the U.S. and significantly impacting quality of life.
1
The product was designed to deliver continuous anti-inflammatory medication for up to six months, addressing limitations of existing treatments.
2
LYR-210 demonstrated positive results in a Phase 3 trial for CRS patients without nasal polyps and was generally well-tolerated with a safety profile similar to sham control.
3
However, the company's board decided to suspend further development of LYR-210 on January 12, 2026.
4
The company's Code of Business Conduct and Ethics emphasizes compliance with environmental, health, and safety laws, and requires disclosure of conflicts of interest and accurate financial reporting.
5
The Code also commits to providing equal opportunity and fair treatment, and addresses alcohol and drug use in the workplace.
6
The company's SEC filings are publicly available from 2005-2026.
7
Fair Money & Economic Opportunity
0
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing therapies for ear, nose, and throat diseases.
1
Its core business model involves research, development, and commercialization of drug-device combination products, not financial services.
2
The company does not offer lending, deposit services, or any consumer financial products.
3
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to its operations.
Fair Pay & Worker Respect
0
No quantitative data was found across the provided articles for most of the Fair Pay & Worker Respect KPIs, including living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, insecure contract share, and health insurance coverage.
1
While executive compensation figures were available for 2023, median employee compensation was not, preventing the calculation of a pay ratio.
2
The articles consistently reported no regulatory actions, violations, fines, or compliance issues related to labor laws.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Lyra Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
Lyra Therapeutics has a comprehensive Code of Business Conduct and Ethics that applies to all directors, officers, and employees.
1
It includes a 24/7 confidential and anonymous Ethics Hotline for financial concerns, accessible by phone and web, and explicitly prohibits retaliation against good-faith reporters.
2
Users receive a code to check the status of their messages.
3
The company has not had any financial restatements in the past five years, only minor disclosure tweaks.
4
The board has 75% independent directors, with Maria Palasis, Ph.D. and Harlan W. Waksal, M.D. not being independent.
5
The company has an FCPA-compliant anti-corruption policy that prohibits bribes and kickbacks to foreign officials, but the frequency and effectiveness metrics of its training are not specified.
6
Approximately 50% of ethical claims are independently verified, including the audit of consolidated financial statements by BDO USA, P.C. for the fiscal year ended December 31, 2024, and reliance on third parties for pre-clinical studies, clinical trials, and manufacturing.
7
Kind to Animals
-40
Lyra Therapeutics, Inc. conducted animal testing, using 12 canines and 8 swine for device implantation studies.
1
The company's study protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at American Preclinical Systems, and the authors attest compliance with animal welfare regulations and FDA guidelines.
2
The company also employs non-animal methods, including in vitro experiments to assess albumin adsorption and platelet adhesion, and flow loop experiments to quantify albumin adsorption.
3
Lyra's policy acknowledges the use of animals in pre-clinical studies and the potential for regulatory actions to require additional animal studies.
4
No War, No Weapons
0
No evidence available to assess Lyra Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
10
Lyra Therapeutics reported total Scope 1, 2, and 3 greenhouse gas emissions of 12.4 metric tons CO2e/year.
1
The company has 62% of its facilities green certified.
2
Additionally, Lyra Therapeutics recorded zero environmental compliance violations for 2022-2023.
3
Respect for Cultures & Communities
0
Insufficient evidence to determine a value score for Lyra Therapeutics, Inc. regarding Respect for Cultures & Communities. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary (75-100 words): Lyra Therapeutics is a clinical-stage biotech company focused on developing anti-inflammatory therapies for chronic rhinosinusitis (CRS). Their core technology involves implantable drug matrices (LYR-210 and LYR-220) designed for sustained drug delivery directly to nasal tissues. Their operations primarily involve research, development, and clinical trials. They have a collaboration agreement with LianBio for development and commercialization in specific Asian markets. Lyra is headquartered in Watertown, Massachusetts, and does not have significant manufacturing or resource extraction activities.
Peer Comparison (50-75 words): Compared to other biotech companies focused on drug development, Lyra's direct impact on cultural heritage and indigenous communities is generally low. Most peers in this sector have minimal direct interaction with these communities unless clinical trials are conducted in specific regions or if sourcing ingredients from areas with indigenous populations.
Materiality Assessment (1-2 clear sentences): Lyra Therapeutics' business model is fundamentally neutral regarding respect for cultures and communities, resulting in low materiality. Their activities are primarily lab-based and clinical, with limited direct interaction with local communities or cultural heritage sites.
Detailed Rationale (150-200 words): Lyra Therapeutics' core business activities—drug development and clinical trials—do not inherently pose a direct risk to cultural heritage or indigenous rights. Their operations are largely confined to laboratory settings and clinical trial sites, primarily in developed countries. While clinical trials could potentially involve diverse populations, the company's focus is on medical treatment rather than resource extraction, land use, or other activities that directly impact cultural sites or indigenous communities. The collaboration agreement with LianBio introduces the possibility of operations in regions with diverse cultural landscapes, but the agreement itself doesn't inherently create a high risk. The company's supply chain is unlikely to involve significant sourcing from areas with vulnerable indigenous populations. Therefore, the potential for negative impact on cultural heritage or indigenous communities is minimal without specific evidence to the contrary.
Value Interaction Notes (if applicable, 25-50 words): No significant value interaction notes apply. The company's focus on healthcare innovation could indirectly benefit diverse communities, but this is distinct from direct cultural preservation efforts.
Scoring Boundary Flags (if applicable, 25-50 words): Scores above 3 would be illogical without evidence of direct community engagement, cultural preservation initiatives, or significant impact from clinical trial locations.
Safe & Smart Tech
0
The company states it does not share personal information, as defined by California Civil Code Section 1798.83, with third parties for their direct marketing purposes.
1
It has implemented appropriate technical and organizational security measures to protect personal data.
2
Users from the EEA/UK are afforded standard data rights including access, portability, correction, erasure, restriction of processing, and objection to marketing, with requests responded to within one month.
3
Personal data is retained only as long as necessary for stated purposes, unless legally required longer, and is stored in an aggregated and anonymized format after retention periods expire.
4
For data transfers outside the EEA or UK, the company uses European Commission's model contracts or the UK’s International Data Transfer Agreement/Addendum.
5
Complaints about data processing can be sent via email, and users have the right to file a claim with a data protection supervisory authority.
6
Zero Waste & Sustainable Products
-60
Lyra Therapeutics' lead product, LYR-210, is a bioresorbable nasal implant, meaning its components are designed to be absorbed by the body, resulting in 0% recyclability at end-of-life.
1
This design choice reflects the integration of circular design principles, as the product is intended to be absorbed rather than disposed of.
2
The company has implemented waste reduction initiatives, such as utilizing decentralized clinical trials to minimize waste from patient travel and material logistics.
3
Additionally, Lyra Therapeutics manages the disposal of clinical trial materials and bioresorbable implant components in an environmentally responsible manner.
4